Statins and other cholesterol-lowering drugs that work the same way (like ezetimibe) lower heart attack and stroke risk equally well for the same amount of cholesterol reduction.
Scientific Claim
The reduction in major vascular events per 1-mmol/L decrease in LDL-C is similar for statins and nonstatin therapies that upregulate LDL receptor expression (e.g., ezetimibe, bile acid sequestrants), with no statistically significant difference in relative risk reduction between these classes.
Original Statement
“The RR for major vascular events per 1-mmol/L (38.7-mg/dL) reduction in LDL-C level was 0.77 (95% CI, 0.71-0.84; P < .001) for statins and 0.75 (95% CI, 0.66-0.86; P = .002) for established nonstatin interventions... (between-group difference, P = .72).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The abstract reports a direct comparison with P-value and confidence intervals; however, full RCT methodology is unverified, so 'associated with' is used conservatively.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aIn EvidenceThat different LDL-C-lowering drug classes produce equivalent cardiovascular risk reduction when matched for magnitude of LDL-C lowering.
That different LDL-C-lowering drug classes produce equivalent cardiovascular risk reduction when matched for magnitude of LDL-C lowering.
What This Would Prove
That different LDL-C-lowering drug classes produce equivalent cardiovascular risk reduction when matched for magnitude of LDL-C lowering.
Ideal Study Design
A meta-analysis of head-to-head RCTs comparing statins vs. nonstatin LDL-C-lowering agents (ezetimibe, PCSK9 inhibitors, etc.) with matched LDL-C reduction targets, using adjudicated major vascular events as primary outcome across 5+ years.
Limitation: Cannot determine if differences exist in safety, adherence, or long-term outcomes beyond 5 years.
Randomized Controlled TrialLevel 1bIn EvidenceThat statins and nonstatin therapies with identical LDL-C-lowering effects produce equivalent cardiovascular outcomes.
That statins and nonstatin therapies with identical LDL-C-lowering effects produce equivalent cardiovascular outcomes.
What This Would Prove
That statins and nonstatin therapies with identical LDL-C-lowering effects produce equivalent cardiovascular outcomes.
Ideal Study Design
A double-blind RCT of 3,000 patients with high LDL-C, randomized to statin vs. ezetimibe, titrated to achieve identical LDL-C targets (e.g., <1.8 mmol/L), with primary outcome: composite major vascular events over 5 years.
Limitation: Limited generalizability to populations with comorbidities or low adherence.
Prospective Cohort StudyLevel 2bThat in real-world practice, patients on nonstatin therapies achieve similar cardiovascular outcomes as those on statins when LDL-C is similarly reduced.
That in real-world practice, patients on nonstatin therapies achieve similar cardiovascular outcomes as those on statins when LDL-C is similarly reduced.
What This Would Prove
That in real-world practice, patients on nonstatin therapies achieve similar cardiovascular outcomes as those on statins when LDL-C is similarly reduced.
Ideal Study Design
A prospective cohort of 10,000 patients on statins vs. nonstatin LDL-lowering agents, matched for baseline LDL-C and achieved LDL-C levels, followed for 7+ years with adjudicated cardiovascular events.
Limitation: Confounding by indication (e.g., nonstatin users may be statin-intolerant with different baseline risk).
Evidence from Studies
Supporting (1)
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
This study found that both statins and other cholesterol-lowering drugs like ezetimibe reduce heart attacks and strokes by about the same amount for every 1-point drop in bad cholesterol — so neither is clearly better than the other for this purpose.